Analysts expect BlackBerry Limited (TSE:BB) to report $-0.02 EPS on December, 19.They anticipate $0.03 EPS change or 300.00% from last quarter’s $0.01 EPS. The stock decreased 3.66% or $0.42 during the last trading session, reaching $11.04. About 2.08 million shares traded or 21.05% up from the average. BlackBerry Limited (TSE:BB) has 0.00% since December 7, 2017 and is . It has underperformed by 15.62% the S&P500. Some Historical BB News: 28/03/2018 – BLACKBERRY 4Q ADJ REV $239M, EST. $215.5M; 09/04/2018 – BlackBerry CEO predicts China will protect intellectual property as it develops more of its own; 06/03/2018 – FACEBOOK LAWYER PAUL GREWAL SAYS BLACKBERRY ‘IS NOW LOOKING TO TAX THE INNOVATION OF OTHERS’ WITH PATENT SUIT -STATEMENT; 22/03/2018 – BLACKBERRY LTD BB.TO – TERMS OF AGREEMENT ARE CONFIDENTIAL; 31/05/2018 – BLACKBERRY LTD – ANNOUNCES NEW SECURITY CREDENTIAL MANAGEMENT SYSTEM; 21/03/2018 – BLACKBERRY TO CONTINUE TESTING SELF DRIVING SOFTWARE ON ROAD; 22/03/2018 – BLACKBERRY CEO TELEVISION INTERVIEW ENDS; 06/03/2018 – BLACKBERRY COMMENTS IN EMAILED STATEMENT; 04/05/2018 – Blackberry CEO: This safety plan would ‘defeat the purpose’ of self-driving cars; 19/03/2018 – BlackBerry and Microsoft Partner to Empower the Mobile Workforce
Among 6 analysts covering Pfizer (NYSE:PFE), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Pfizer had 8 analyst reports since August 1, 2018 according to SRatingsIntel. Bank of America maintained Pfizer Inc. (NYSE:PFE) on Wednesday, August 1 with “Buy” rating. On Thursday, August 23 the stock rating was maintained by Barclays Capital with “Equal-Weight”. BMO Capital Markets downgraded Pfizer Inc. (NYSE:PFE) on Thursday, November 1 to “Market Perform” rating. The stock of Pfizer Inc. (NYSE:PFE) has “Sell” rating given on Tuesday, November 6 by Citigroup. The company was maintained on Thursday, August 23 by Morgan Stanley. The firm has “Neutral” rating by Credit Suisse given on Wednesday, October 31. BMO Capital Markets maintained it with “Outperform” rating and $44 target in Wednesday, August 1 report. Credit Suisse maintained it with “Neutral” rating and $40 target in Wednesday, August 1 report. See Pfizer Inc. (NYSE:PFE) latest ratings:
06/11/2018 Broker: Citigroup Old Rating: Sell New Rating: Sell Old Target: $34 New Target: $37 Maintain
01/11/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Downgrade
31/10/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Neutral Old Target: $40 New Target: $42 Maintain
23/08/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $43 New Target: $45 Maintain
23/08/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $38 New Target: $40 Maintain
01/08/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $42 New Target: $43 Maintain
01/08/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $42 New Target: $44 Maintain
01/08/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Neutral Old Target: $39 New Target: $40 Maintain
Since June 6, 2018, it had 0 insider buys, and 2 sales for $1.92 million activity. $1.50M worth of stock was sold by SUSMAN SALLY on Friday, July 20. $418,774 worth of Pfizer Inc. (NYSE:PFE) shares were sold by OLSON LAURIE J.
Investors sentiment decreased to 0.78 in 2018 Q2. Its down 0.11, from 0.89 in 2018Q1. It is negative, as 52 investors sold Pfizer Inc. shares while 754 reduced holdings. 112 funds opened positions while 518 raised stakes. 3.98 billion shares or 0.73% less from 4.01 billion shares in 2018Q1 were reported. Schaper Benz And Wise Investment Counsel Inc Wi has 227,460 shares. Northstar Gp holds 0.18% of its portfolio in Pfizer Inc. (NYSE:PFE) for 9,842 shares. Moreover, Louisiana State Employees Retirement Systems has 0.56% invested in Pfizer Inc. (NYSE:PFE). Perkins Coie Tru reported 58,776 shares stake. Hyman Charles D has invested 0.45% in Pfizer Inc. (NYSE:PFE). Fairview Capital Invest Mgmt Ltd Limited Liability Company reported 7,325 shares. Brown Brothers Harriman reported 288,737 shares. Stelac Advisory Ltd Co has invested 0.07% in Pfizer Inc. (NYSE:PFE). Beech Hill holds 2.55% in Pfizer Inc. (NYSE:PFE) or 125,414 shares. At Savings Bank has 0.09% invested in Pfizer Inc. (NYSE:PFE). Prio Wealth Limited Partnership holds 1.01 million shares or 1.81% of its portfolio. 251,899 are owned by Captrust Financial Advsrs. Sol Mngmt invested in 0.39% or 37,421 shares. Notis accumulated 14,650 shares or 0.32% of the stock. Brookstone Capital Mgmt has invested 0.63% in Pfizer Inc. (NYSE:PFE).
The stock decreased 0.35% or $0.16 during the last trading session, reaching $44.98. About 30.54 million shares traded or 37.29% up from the average. Pfizer Inc. (NYSE:PFE) has risen 19.90% since December 7, 2017 and is uptrending. It has outperformed by 4.28% the S&P500. Some Historical PFE News: 03/04/2018 – Pfizer and P&G are in talks on sale of consumer business, though far apart in price; 21/03/2018 – Reckitt Benckiser pulls out of Pfizer consumer health auction; 16/04/2018 – AstraZeneca Presents lmfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting; 01/05/2018 – PFIZER REAFFIRMS ALL COMPONENTS OF 2018 FINL GUIDANCE; 15/05/2018 – FDA Granted Approval of Retacrit to Hospira Inc., a Pfizer Company; 01/05/2018 – Pfizer: Several Potential Near-Term Opportunities in Core Therapeutic Areas; 29/03/2018 – This is really interesting: Watch out Alnylam/Ionis: Pfizer’s positive PhIII tafamidis data makes drug a contender $PFE $IONS -4.4% $ALNY -4.8% AKCA -11.5% @BrittanyMeiling; 16/05/2018 – PHASE lll IMPOWER150 STUDY SHOWED GENENTECH’S TECENTRIQ AND AVASTIN PLUS CARBOPLATIN AND PACLITAXEL HELPED PEOPLE WITH A SPECIFIC TYPE OF METASTATIC LUNG CANCER LIVE SIGNIFICANTLY LONGER COMPARED TO; 16/05/2018 – NOVARTIS AG NOVN.S CEO SAYS CONTINUES TO BELIEVE KISQUALI IMPORTANT BUT NOT AS LARGE AS ONCE THOUGHT; 17/05/2018 – PFIZER INC – TREATMENT WITH LYRICA AT LOWER DOSE DID NOT RESULT IN STATISTICALLY SIGNIFICANT REDUCTION IN SEIZURE FREQUENCY VERSUS PLACEBO
More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “Pfizer Receives FDA Approval For AML Drug – Seeking Alpha” on November 27, 2018, also Investorplace.com with their article: “Mondayâ€™s Vital Data: Pfizer, Goldman Sachs and Caterpillar – Investorplace.com” published on December 03, 2018, Investorplace.com published: “Pfizer Stock Has Multiple Positive Catalysts – Investorplace.com” on November 21, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer’s Rituxan biosimilar successful in late-stage study; shares up 1% premarket – Seeking Alpha” published on December 03, 2018 as well as Gurufocus.com‘s news article titled: “Phil Fisher: When to Buy Stocks – GuruFocus.com” with publication date: December 06, 2018.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $260.01 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 11.36 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.